Using iPSC-derived human DA neurons from opioid-dependent subjects to study dopamine dynamics

Brain and Behavior

Volumn 6, Issue 8, 2016, Pages

  Sheng, Yang ^a   Filichia, Emily ^a   Shick, Elizabeth ^b   Preston, Kenzie L ^c   Phillips, Karran A ^c   Cooperman, Leslie ^b   Lin, Zhicheng ^d   Tesar, Paul ^b   Hoffer, Barry ^a   Luo, Yu ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

3 VNTR; hDAT gene; iPSCs; opioid dependent

Indexed keywords

DELTA OPIATE RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; HEPATOCYTE NUCLEAR FACTOR 3BETA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; KAPPA OPIATE RECEPTOR; LENTIVIRUS VECTOR; MU OPIATE RECEPTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 4; PENTRAXIN 3; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR PAX6; VALPROIC ACID; VESICULAR MONOAMINE TRANSPORTER 2; ENZYME INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FEMALE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INDUCED PLURIPOTENT STEM CELL; MALE; NERVE CELL DIFFERENTIATION; NUCLEAR REPROGRAMMING; OPIATE ADDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; VARIABLE NUMBER OF TANDEM REPEAT; WNT SIGNALING PATHWAY; CELL DIFFERENTIATION; DRUG EFFECTS; GENETICS; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADULT; CELL DIFFERENTIATION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; OPIOID-RELATED DISORDERS; POLYMORPHISM, GENETIC; VALPROIC ACID; YOUNG ADULT;

EID: 84971444981     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.491     Document Type: Article

References (61)

1. Ambrose, L. M., S. M. Gallagher, E. M. Unterwald, and E. J. Van Bockstaele. 2006. Dopamine-D1 and delta-opioid receptors co-exist in rat striatal neurons. Neurosci. Lett. 399:191–196.
2. Atmaca, A., S. E. Al-Batran, A. Maurer, A. Neumann, T. Heinzel, B. Hentsch, et al. 2007. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer 97:177–182.
3. Bannon, M. J. 2005. The dopamine transporter: role in neurotoxicity and human disease. Toxicol. Appl. Pharmacol. 204:355–360.
4. Bannon, M. J., B. Pruetz, E. Barfield, and C. J. Schmidt. 2004. Transcription factors specifying dopamine phenotype are decreased in cocaine users. NeuroReport 15:401–404.
5. Chateauvieux, S., F. Morceau, M. Dicato, and M. Diederich. 2010. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010:1–18.
6. Chefer, V. I., C. M. Backman, E. D. Gigante, and T. S. Shippenberg. 2013. Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology 38:2623–2631.
7. Chiu, C. T., G. Liu, P. Leeds, and D. M. Chuang. 2011. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36:2406–2421.
8. Crettol, S., J. Besson, M. Croquette-Krokar, R. Hammig, I. Gothuey, M. Monnat, et al. 2008. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 32:1722–1727.
9. Devine, M. J., M. Ryten, P. Vodicka, A. J. Thomson, T. Burdon, H. Houlden, et al. 2011. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat. Commun. 2:440.
10. van Dyck, C. H., R. T. Malison, L. K. Jacobsen, J. P. Seibyl, J. K. Staley, M. Laruelle, et al. 2005. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J. Nucl. Med. 46:745–751.
11. Egawa, N., S. Kitaoka, K. Tsukita, M. Naitoh, K. Takahashi, T. Yamamoto, et al. 2012. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4:145ra104.
12. Fuke, S., S. Suo, N. Takahashi, H. Koike, N. Sasagawa, and S. Ishiura. 2001. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics. J. 1:152–156.
13. Garzon, M., and V. M. Pickel. 2001. Plasmalemmal mu-opioid receptor distribution mainly in nondopaminergic neurons in the rat ventral tegmental area. Synapse 41:311–328.
14. Gerra, G., L. Somaini, C. Leonardi, E. Cortese, I. Maremmani, M. Manfredini, et al. 2014. Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Res. 215:202–207.
15. van de Giessen, E., M. M. de Win, M. W. Tanck, W. van den Brink, F. Baas, and J. Booij. 2009. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J. Nucl. Med. 50:45–52.
16. Guo, X., M. H. Disatnik, M. Monbureau, M. Shamloo, D. Mochly-Rosen, and X. Qi. 2013. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J. Clin. Invest. 123:5371–5388.
17. Halikas, J. A., B. A. Center, V. L. Pearson, G. A. Carlson, and F. Crea. 2001. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Hum. Psychopharmacol. 16:257–264.
18. Hall, F. S., I. Sora, and G. R. Uhl. 2003. Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 28:620–628.
19. Hamilton, R. A., W. R. Garnett, B. J. Kline, and J. M. Pellock. 1981. Effects of food on valproic acid absorption. Am. J. Hosp. Pharm. 38:1490–1493.
20. HD iPSC Consortium. 2012. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264–278.
21. Heinz, A., and D. Goldman. 2000. Genotype effects on neurodegeneration and neuroadaptation in monoaminergic neurotransmitter systems. Neurochem. Int. 37:425–432.
22. Hyman, S. E., and R. C. Malenka. 2001. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Rev. Neurosci. 2:695–703.
23. Hyman, S. E., R. C. Malenka, and E. J. Nestler. 2006. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci. 29:565–598.
24. Johnson, S. W., and R. A. North. 1992. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12:483–488.
25. Kalda, A., L. T. Heidmets, H. Y. Shen, A. Zharkovsky, and J. F. Chen. 2007. Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice. Behav. Brain Res. 181:76–84.
26. Koob, G. F., and F. E. Bloom. 1988. Cellular and molecular mechanisms of drug dependence. Science 242:715–723.
27. Krasnova, I. N., and J. L. Cadet. 2009. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 60:379–407.
28. Kriks, S., J. W. Shim, J. Piao, Y. M. Ganat, D. R. Wakeman, Z. Xie, et al. 2011. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480:547–551.
29. Lieberman, R., E. S. Levine, H. R. Kranzler, C. Abreu, and J. Covault. 2012. Pilot study of iPS-derived neural cells to examine biologic effects of alcohol on human neurons in vitro. Alcohol. Clin. Exp. Res. 36:1678–1687.
30. Mabrouk, O. S., M. Volta, M. Marti, and M. Morari. 2008. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism. J. Neurochem. 107:1647–1659.
31. Margolis, E. B., G. O. Hjelmstad, A. Bonci, and H. L. Fields. 2003. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J. Neurosci. 23:9981–9986.
32. Margolis, E. B., H. L. Fields, G. O. Hjelmstad, and J. M. Mitchell. 2008. Delta-opioid receptor expression in the ventral tegmental area protects against elevated alcohol consumption. J. Neurosci. 28:12672–12681.
33. McLellan, A. T., L. Luborsky, J. Cacciola, J. Griffith, F. Evans, H. L. Barr, and C. P. O'Brien. 1985. New data from the Addiction Severity Index. Reliability and validity in three centers. J. Nerv. Ment. Dis. 173:412–423.
34. Mendez, M., and M. Morales-Mulia. 2008. Role of mu and delta opioid receptors in alcohol drinking behaviour. Curr. Drug Abuse Rev. 1:239–252.
35. Mill, J., P. Asherson, I. Craig, and U. M. D'Souza. 2005. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet. 6:3.
36. Miller, G. M., and B. K. Madras. 2002. Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol. Psychiatry 7:44–55.
37. Monti, B., E. Polazzi, and A. Contestabile. 2009. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr. Mol. Pharmacol. 2:95–109.
38. Monti, B., V. Gatta, F. Piretti, S. S. Raffaelli, M. Virgili, and A. Contestabile. 2010. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox. Res. 17:130–141.
39. Nestler, E. J. 2001. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2:119–128.
40. Nielsen, D. A., S. C. Hamon, and T. R. Kosten. 2013. The kappa-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr. Genet. 23:225–232.
41. Peckys, D., and G. B. Landwehrmeyer. 1999. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 88:1093–1135.
42. Sheng, Y., E. Filichia, E. Shick, K. L. Preston, K. A. Phillips, L. Cooperman, et al. 2016. Lower Dopamine D2 Receptor Expression Levels in Human Dopaminergic Neurons Derived From Opioid-Dependent iPSCs. Am. J. Psychiatry 173:429–431.
43. Shimada, S., S. Kitayama, C. L. Lin, A. Patel, E. Nanthakumar, P. Gregor, et al. 1991. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254:576–578.
44. Shumay, E., J. S. Fowler, and N. D. Volkow. 2010. Genomic features of the human dopamine transporter gene and its potential epigenetic States: implications for phenotypic diversity. PLoS One 5:e11067.
45. Smith, A. D., D. A. Kozlowski, M. C. Bohn, and M. J. Zigmond. 2005. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp. Neurol. 193:420–426.
46. Smith, L. A., V. R. Cornelius, J. M. Azorin, G. Perugi, E. Vieta, A. H. Young, et al. 2010. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J. Affect. Disord. 122:1–9.
47. Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676.
48. Takahashi, K., K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, et al. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872.
49. Thomsen, M., F. S. Hall, G. R. Uhl, and S. B. Caine. 2009. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J. Neurosci. 29:1087–1092.
50. Tsai, L. K., Y. Leng, Z. Wang, P. Leeds, and D. M. Chuang. 2010. The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology 35:2225–2237.
51. Vandenbergh, D. J., A. M. Persico, A. L. Hawkins, C. A. Griffin, X. Li, E. W. Jabs, et al. 1992. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104–1106.
52. VanNess, S. H., M. J. Owens, and C. D. Kilts. 2005. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 6:55.
53. Volkow, N. D., J. S. Fowler, G. J. Wang, and J. M. Swanson. 2004. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry 9:557–569.
54. Volkow, N. D., J. S. Fowler, G. J. Wang, J. M. Swanson, and F. Telang. 2007. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch. Neurol. 64:1575–1579.
55. Wang, J., S. K. Michelhaugh, and M. J. Bannon. 2007. Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells. Eur. J. Neurosci. 25:1982–1986.
56. Wise, R. A. 2008. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox. Res. 14:169–183.
57. Wise, R. A., and M. A. Bozarth. 1987. A psychomotor stimulant theory of addiction. Psychol. Rev. 94:469–492.
58. Wise, R. A., P. Leone, R. Rivest, and K. Leeb. 1995. Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse 21:140–148.
59. Yamada, M., K. Groshan, C. T. Phung, M. Yamada, T. Hisamitsu, and E. Richelson. 1997. The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain. Brain Res. Mol. Brain Res. 44:12–20.
60. Yamanaka, S. 2009. A fresh look at iPS cells. Cell 137:13–17.
61. Zullino, D. F., Y. Khazaal, J. Hattenschwiler, F. Borgeat, and J. Besson. 2004. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today (Barc) 40:603–619.